Radiopharmaceuticals for therapy by F.F. (Russ) Knapp and Ashutosh Dash

Matteis, Gianluca De; Mansi, Luigi

doi:10.1007/s00259-017-3626-3

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A radiotracer can detect processes such as local blood flow, cellular metabolism, the expression of receptors in various cell types, neurotransmitter activity, trafficking and cellular homing, tissue invasion, and programmed cell death [ 39 ]. PET/CT and SPECT/CT devices in combination mode [ 40 ] allow pathological investigation of metabolism and morphology of organs, in addition to assessing treatment response [ 41 ].…”

Section: Radiopharmaceutical Radiometric Counters and Preclinical Ima...mentioning

confidence: 99%

“…One of the fields of application of research on the optimization of radiopharmaceuticals labeled with 64 Cu is to find bifunctional chelators for this radioisotope that are useful for detecting Aβ plaques. Nilantha, et al [ 39 ] has studied these mechanics in vitro and in vivo using triazacyclonane and 2,11-diaza [3.3]-(2,6)pyridinophane(N4) macrocycles, as well as 2-phenyl-benzothiazole segments, to create chelated bifunctional structures. The in vitro binding study with 64 Cu-radiolabeled complexes administered to Aβ40 fibrils in multiwall wells allowed for the calculation of the related radioactivity, through a Gamma 8000 counter containing a NaI crystal (Beckman Instruments, Inc., Irvine, CA, USA).…”

Section: Validation Of Radiopharmaceuticals In Vitro By γ-Countermentioning

confidence: 99%

See 1 more Smart Citation

An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics

et al. 2023

View full text Add to dashboard Cite

Radionuclides are unstable isotopes that mainly emit alpha (α), beta (β) or gamma (γ) radiation through radiation decay. Therefore, they are used in the biomedical field to label biomolecules or drugs for diagnostic imaging applications, such as positron emission tomography (PET) and/or single-photon emission computed tomography (SPECT). A growing field of research is the development of new radiopharmaceuticals for use in cancer treatments. Preclinical studies are the gold standard for translational research. Specifically, in vitro radiopharmaceutical studies are based on the use of radiopharmaceuticals directly on cells. To date, radiometric β- and γ-counters are the only tools able to assess a preclinical in vitro assay with the aim of estimating uptake, retention, and release parameters, including time- and dose-dependent cytotoxicity and kinetic parameters. This review has been designed for researchers, such as biologists and biotechnologists, who would like to approach the radiobiology field and conduct in vitro assays for cellular radioactivity evaluations using radiometric counters. To demonstrate the importance of in vitro radiopharmaceutical assays using radiometric counters with a view to radiogenomics, many studies based on 64Cu-, 68Ga-, 125I-, and 99mTc-labeled radiopharmaceuticals have been revised and summarized in this manuscript.

show abstract

Section: Radiopharmaceutical Radiometric Counters and Preclinical Ima...mentioning

confidence: 99%

Section: Validation Of Radiopharmaceuticals In Vitro By γ-Countermentioning

confidence: 99%